The biotech is developing very targeted cancer treatments that aim to reduce the collateral damage done by the drug
BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) is looking to strengthen its intellectual property base with four UK patent applications related to several novel cancer-specific antigen pairs or “fingerprints” across a range of oncology indications.
The technology being put forward for patent protection will support the development of a pipeline of highly selective cancer therapeutics that use the company’s Bi-Cygni approach.
By spotting specific patterns on the surface of a cell, rather than a single cancer identifier, Bi-Cygni treatments are expected to target cancer with superior specificity while eradicating collateral damage.
Chief executive Tiffany Thorn said: “The new patents, if approved, will provide broad protection for our pipeline assets, allowing the development of several generations of cancer-selective Bi-Cygni therapeutics across a wide range of solid tumour and haematological cancers that constitute areas of urgent unmet need.”
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…
In exchange for publishing services rendered by the Company on behalf of BiVictriX Therapeutics PLC named herein, including the promotion by the Company of BiVictriX Therapeutics PLC in any Content on the Site, the…
FOR OUR FULL DISCLAIMER CLICK HERE
Credit: Source link
